Business / Finance RSS Feed - Business / Finance

Protein Sciences, UNIGEN agree to supply Flublok influenza vaccine for the U.S. market from Japan

Protein Sciences, UNIGEN agree to supply Flublok influenza vaccine for the U.S. market from Japan

Protein Sciences Corporation (Meriden, CT and Pearl River, NY) and UMN Pharma Inc. (Akita, Akita prefecture, Japan) announced today that Protein Sciences and UNIGEN Inc., a joint venture of UMN and IHI Corporation (Koto-ku, Tokyo, Japan), entered into an agreement to source bulk Flublok influenza vaccine from Japan for the U.S. market. [More]
Apellis Pharmaceuticals completes $47.1M Series D preferred stock financing

Apellis Pharmaceuticals completes $47.1M Series D preferred stock financing

Apellis Pharmaceuticals, Inc., today announced that it has completed a $47.1 million Series D preferred stock financing, co-led by new investors Cormorant Asset Management, Hillhouse Capital Group and venBio Global Strategic Fund, joining existing investors Morningside Venture Investments, AJU IB Investment, and Epidarex Capital. [More]
Neurocrine Biosciences reports net loss of $29.3 million for fourth quarter 2015

Neurocrine Biosciences reports net loss of $29.3 million for fourth quarter 2015

Neurocrine Biosciences, Inc. today announced its financial results for the quarter and year ended December 31, 2015. [More]
ASTRO encourages policymakers to increase financial support for cancer research in FY 2017 Budget

ASTRO encourages policymakers to increase financial support for cancer research in FY 2017 Budget

The American Society for Radiation Oncology commends the proposed investment in cancer-related research announced in the Fiscal Year 2017 Budget released yesterday by the White House. [More]
FDA requests $5.1 billion budget for FY 2017 to protect and promote public health

FDA requests $5.1 billion budget for FY 2017 to protect and promote public health

The U.S. Food and Drug Administration is requesting a total budget of $5.1 billion to protect and promote the public health as part of the President's fiscal year (FY) 2017 budget – an eight percent increase over the enacted budget for FY 2016. [More]
Landauer's revenues decrease 2.7% to $36.5 million in first fiscal quarter of 2016

Landauer's revenues decrease 2.7% to $36.5 million in first fiscal quarter of 2016

Landauer, Inc., a recognized leader in personal and environmental radiation measurement and monitoring, outsourced medical physics services and high quality medical consumable accessories, today reported financial results for its fiscal 2016 first quarter ended December 31, 2015. [More]
Wayne State inks exclusive license agreement with TRImaran Pharma for novel class of drugs

Wayne State inks exclusive license agreement with TRImaran Pharma for novel class of drugs

Wayne State University recently entered into an exclusive license agreement with TRImaran Pharma Inc. for a class of novel drugs developed at Wayne State University that aims to offer hope in the treatment of post-traumatic stress disorders (PTSD), depression, ADHD and other neurological disorders. [More]
Study: Prior surgical abortion appears to increase risk of later preterm birth

Study: Prior surgical abortion appears to increase risk of later preterm birth

Surgical methods used in a common form of abortion or to clear the womb after a spontaneous miscarriage appears to significantly increase the risk of a later preterm birth, say researchers at Thomas Jefferson University who analyzed 36 studies that enrolled more than 1 million women. [More]
Cell Therapy Catapult becomes Cell and Gene Therapy Catapult

Cell Therapy Catapult becomes Cell and Gene Therapy Catapult

The Cell Therapy Catapult, the UK organisation dedicated to the growth of the UK cell and gene therapy industry by bridging the gap between scientific research and commercialisation, today announces the official change of its name to the Cell and Gene Therapy Catapult. [More]
Cantel Medical to buy Sterility Assurance Monitoring Products division of NAMSA for $13.5 million

Cantel Medical to buy Sterility Assurance Monitoring Products division of NAMSA for $13.5 million

CANTEL MEDICAL CORP., has entered into a definitive agreement with North American Science Associates, Inc. to acquire NAMSA's Sterility Assurance Monitoring Products division for $13.5 million in cash consideration. For the year ending December 31, 2015 this business had adjusted sales of $5.7 million. [More]
Edwards Lifesciences' global sales grow 8.6% to $671.1 million in fourth quarter 2015

Edwards Lifesciences' global sales grow 8.6% to $671.1 million in fourth quarter 2015

Edwards Lifesciences Corporation, the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today reported financial results for the quarter ended December 31, 2015. [More]
ST Asia signs licensing deal with PharmaMar to distribute new multiple myeloma drug in South East Asia

ST Asia signs licensing deal with PharmaMar to distribute new multiple myeloma drug in South East Asia

International biopharmaceutical company Specialised Therapeutics Asia will supply and distribute a novel oncology drug candidate throughout South East Asia, following an exclusive licensing deal with European pharmaceutical company PharmaMar. [More]

Hillenbrand acquires Red Valve for $131.9 million

Hillenbrand, Inc. has completed its previously announced acquisition of Red Valve Company, Inc. for a purchase price of $131.9 million in cash, including $3.3 million for related real estate. [More]
Aflac's total revenues decrease 3.5% to $5.3 billion in fourth quarter 2015

Aflac's total revenues decrease 3.5% to $5.3 billion in fourth quarter 2015

Aflac Incorporated today reported its fourth quarter results. Reflecting the weaker yen/dollar exchange rate, total revenues decreased 3.5% to $5.3 billion during the fourth quarter of 2015, compared with $5.5 billion in the fourth quarter of 2014. Net earnings were $730 million, or $1.71 per diluted share, compared with $703 million, or $1.57 per share, a year ago. [More]
FedMed gains access to Trovagene's Precision Cancer Monitoring tests and service

FedMed gains access to Trovagene's Precision Cancer Monitoring tests and service

Trovagene, Inc., a developer of cell-free molecular diagnostics, announced today that it has entered into an agreement with FedMed, Inc. establishing health benefit access to Trovagene's full line of Precision Cancer Monitoring (PCM) tests and services. [More]
HUYA, Eisai sign exclusive license agreement for HBI-8000 in Japan and other Asian countries

HUYA, Eisai sign exclusive license agreement for HBI-8000 in Japan and other Asian countries

HUYA Bioscience International President, CEO, Executive Chairman & Founder Dr. Mireille Gillings announced that Eisai Co., Ltd. has acquired from HUYA an exclusive license agreement for HBI-8000 in Japan, South Korea, Thailand, Malaysia, Indonesia, Philippines, Vietnam and Singapore. [More]
Allergan and AstraZeneca partner to develop, commercialize ATM-AVI for MBL-producing pathogens

Allergan and AstraZeneca partner to develop, commercialize ATM-AVI for MBL-producing pathogens

Allergan plc today announced that it has entered into a global agreement with AstraZeneca to develop and commercialize ATM-AVI, an investigational, fixed-dose antibiotic combining aztreonam and avibactam. [More]
Refugee women have higher risk of giving birth too early than non-refugee immigrants

Refugee women have higher risk of giving birth too early than non-refugee immigrants

Refugee women who come to Canada have greater risk of giving birth prematurely than non-refugee immigrants, a study by a St. Michael's Hospital researcher has found. Those risks are fueled by the fact that the preterm birth rate was 7.1 per cent among secondary refugees - those who spent more than six months in a transit country before arriving in Canada -compared to five per cent among secondary, non-refugee immigrants. [More]
CosmosID announces $6M in Series B funding round

CosmosID announces $6M in Series B funding round

CosmosID, the leading genomic big data company focused on microbiome research, outbreak investigations, and infectious disease diagnostics, using next-generation DNA sequencing, announced $6M in Series B funding. [More]
SCIO Health Analytics announces acquisition of Clear Vision Information Systems

SCIO Health Analytics announces acquisition of Clear Vision Information Systems

SCIO Health Analytics today announced it has acquired Clear Vision Information Systems of Westlake Village, California, creators of an analytics solution and services suite that provides risk adjustment and quality metric strategies for health plans and providers. [More]
Advertisement
Advertisement